Kévin Leguay

Kévin Leguay

Auto-generated profile, based on publicly available information

Kévin Leguay

Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
KLKévin Leguay
Kévin Leguay
BDBarbara Decelle
Barbara Decelle
IEIslam Elkholi
Islam Elkholi
MBMichel Bouvier
Michel Bouvier
JCJean-François Côté
Jean-François Côté
SCSebastien Carreno
Sebastien Carreno
At mitotic entry, reorganization of the actomyosin cortex prompts cells to round-up. Proteins of the ezrin, radixin, and moesin family (ERM) play essential roles in this process by linking actomyosin forces to the plasma membrane. Yet, the cell-cycle signal that activates ERMs at mitotic entry is unknown. By screening a compound library using newly developed biosensors, we discovered that drugs that disassemble microtubules promote ERM activation. We further demonstrated that disassembly of interphase microtubules at mitotic entry directs ERM activation and metaphase cell rounding through GEF-H1, a Rho-GEF inhibited by microtubule binding, RhoA, and its kinase effector SLK. We finally demonstrated that GEF-H1 and Ect2, another Rho-GEF previously identified to control actomyosin forces, act together to drive activation of ERMs and cell rounding in metaphase. In summary, we report microtubule disassembly as a cell-cycle signal that controls a signaling network ensuring that actomyosin forces are efficiently integrated at the plasma membrane to promote cell rounding at mitotic entry.

22 September 2020 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
CJCamille Valérie De Jamblinne
Camille Valérie De Jamblinne
BDBarbara Decelle
Barbara Decelle
MDMehrnoush Dehghani
Mehrnoush Dehghani
MJMathieu Joseph
Mathieu Joseph
NSNeera Sriskandarajah
Neera Sriskandarajah
SCSebastien Carreno
Sebastien Carreno
Proteins of the ezrin, radixin, and moesin (ERM) family control cell and tissue morphogenesis. We previously reported that moesin, the only ERM in Drosophila, controls mitotic morphogenesis and epithelial integrity. We also found that the Pp1-87B phosphatase dephosphorylates moesin, counteracting its activation by the Ste20-like kinase Slik. To understand how this signaling pathway is itself regulated, we conducted a genome-wide RNAi screen, looking for new regulators of moesin activity. We identified that Slik is a new member of the striatin-interacting phosphatase and kinase complex (STRIPAK). We discovered that the phosphatase activity of STRIPAK reduces Slik phosphorylation to promote its cortical association and proper activation of moesin. Consistent with this finding, inhibition of STRIPAK phosphatase activity causes cell morphology defects in mitosis and impairs epithelial tissue integrity. Our results implicate the Slik–STRIPAK complex in the control of multiple morphogenetic processes.

1 April 2021 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
KLKévin Leguay
Kévin Leguay
BDBarbara Decelle
Barbara Decelle
YHYu Yan He
Yu Yan He
APAnthony Pagniez
Anthony Pagniez
MHMireille Hogue
Mireille Hogue
SCSebastien Carreno
Sebastien Carreno
Ezrin, radixin and moesin compose the family of ERM proteins. They link actin filaments and microtubules to the plasma membrane to control signaling and cell morphogenesis. Importantly, their activity promotes invasive properties of metastatic cells from different cancer origins. Therefore, a precise understanding of how these proteins are regulated is important for the understanding of the mechanism controlling cell shape, as well as providing new opportunities for the development of innovative cancer therapies. Here, we developed and characterized novel bioluminescence resonance energy transfer (BRET)-based conformational biosensors, compatible with high-throughput screening, that monitor individual ezrin, radixin or moesin activation in living cells. We showed that these biosensors faithfully monitor ERM activation and can be used to quantify the impact of small molecules, mutation of regulatory amino acids or depletion of upstream regulators on their activity. The use of these biosensors allowed us to characterize the activation process of ERMs that involves a pool of closed-inactive ERMs stably associated with the plasma membrane. Upon stimulation, we discovered that this pool serves as a cortical reserve that is rapidly activated before the recruitment of cytoplasmic ERMs.

1 January 2025 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
KLKévin Leguay
Kévin Leguay
OKOliver Kent
Oliver Kent
The KRAS gene is nearly ubiquitously subjected to activating mutation in pancreatic adenocarcinomas (PDAC), occurring at a frequency of over 90% in tumors. Mutant KRAS drives sustained signaling through the MAPK pathway to affect frequently disrupted cancer phenotypes including transcription, proliferation and cell survival. Recent research has shown that PDAC tumor growth and survival required a guanine nucleotide exchange factor for RAS homolog family member A (RhoA) called GEF-H1. The GEF-H1 protein, encoded by the ARHGEF2 gene, is a microtubule-associated GEF for RhoA that promotes invasion-migration of PDAC cells via activation of RhoA. Unexpectedly, independent of its RhoGEF activity, GEF-H1 was found to potentiate MAPK signaling by scaffolding protein phosphatase 2A (PP2A) to the kinase suppressor of Ras 1 (KSR-1). In a feedback-dependent manner, enhanced MAPK activity drives expression of ARHGEF2 via regulation of transcription factors ETS and SP, and the RAS responsive element-binding protein 1 (RREB1). RREB1 a negative regulator of ARHGEF2 expression, is downregulated in PDAC cells, which permits sustained expression of GEF-H1 for PDAC tumor survival and subsequent MAPK pathway activation. Given that MAPK targeted therapies show limited clinical efficacy, highlights the need for novel targets. This review describes the unexpected complexity of GEF-H1 function leading to positive feedback that potentiates RAS-MAPK signaling and suggests inhibition of GEF-H1 as a therapeutic strategy for RAS-driven cancers.

4 June 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KLKévin Leguay
Kévin Leguay
MAMariana Acevedo
Mariana Acevedo
ECEva Colic
Eva Colic
PPPreya U. Patel
Preya U. Patel
SSSaeideh Shamsi
Saeideh Shamsi
OKOliver A. Kent
Oliver A. Kent
Therapeutic protein replacement has demonstrated pre-clinical and clinical efficacy in neurological disorders but has not been used clinically for Fragile X syndrome (FXS), a genetic neurodevelopmental disorder caused by loss of Fragile X messenger ribonucleoprotein (FMRP). FXS results from a triplet repeat expansion of over 200 CGG repeats in the 5'-UTR of the FMR1 gene leading to epigenetic silencing of FMRP. Currently, no clinically approved disease-modifying treatments for FXS exist. Recently, a tat-conjugated FMRP fragment encompassing residues 1-297 (FMRP N-tat) was shown to restore aspects of neuronal function in a mouse model of FXS. Promising in vivo data hinted to the therapeutic potential of FMRP N-tat. Herein, affinity purification mass spectrometry was used to identify the FMRP N-tat interactome in tsA-201 FMR1 knockout cells and FXS patient iPSC-derived neurons. The FMRP N-tat interactome included RNA binding proteins and constituents of the ribosome, which aligned closely with the known functions of FMRP. Further, the FMRP N-tat associated proteins included FXR2, STAU1, TRIM28, C1QBP, VDAC2, and several ribosomal proteins to regulate mRNA stability, cellular stress responses, mitochondrial function, and translation. The results highlight the potential of FMRP N-tat to orchestrate assembly of factors to correct lost function in FMRP deficient cells.

27 May 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FBFabien Binamé
Fabien Binamé
KLKevin Leguay
Kevin Leguay
CSCaroline Spenlé
Caroline Spenlé
MHMichaël Van Der Heyden
Michaël Van Der Heyden
OKOliver A. Kent
Oliver A. Kent
Dominique BagnardDominique Bagnard
Dominique Bagnard
In the absence of effective remyelination therapies for neurodegenerative disorders, we have synthesized FTX-101, a therapeutic peptide rationally designed to enhance the recruitment and maturation of oligodendrocyte precursors. Given that Sema3A signaling through the NRP1/Plexin-A1 receptor complex inhibits remyelination, we employed FTX-101 to disrupt the assembly of this receptor complex at the transmembrane interface. We conducted in vitro analyses to assess the effects on the migration, differentiation, and myelination of oligodendrocytes. FTX-101 was evaluated in a murine oligodendroglial cell line as well as in oligodendrocytes derived from human fibroblasts. FTX-101 functions as a membrane-targeting peptide with exceptional attributes. Notably, while of lipophilic nature it demonstrates water solubility, it is highly specific for the NRP1/Plexin-A1 receptor system and when lyophilized remains stable for an extended amount of time. Our findings indicated that FTX-101 effectively disrupts the NRP1/Plexin-A1 receptor complex and mitigated the inhibitory influence of Sema3A on oligodendrocyte migration and differentiation, thereby facilitating increased myelin sheathing around axons. FTX-101 enhanced the recruitment of oligodendrocytes and promoted myelination, addressing critical medical needs in demyelinating conditions. Specificity, solubility in water, and enduring stability render FTX-101 a highly promising candidate for a first-in-class therapeutic agent.